Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
DNA Capital is a healthcare investment firm founded in 2016, with offices located in São Paulo, Brazil, and San Francisco, California. The firm is part of the Bueno family's broader investment platform, which has a total AUM of approximately $3.5 billion across various strategic holdings, including DASA, the largest diagnostics company in Latin America and the fifth largest globally. DNA Capital operates as a multi-stage investor, focusing on companies at various stages from pre-seed to growth equity.
The firm has established itself as a significant player in the healthcare investment space, particularly in Latin America, where it has a strong presence. DNA Capital's investment strategy emphasizes ethical and humane products and services, aligning with its commitment to driving innovation and growth in the healthcare sector. The firm has built a portfolio of 24 companies, showcasing its ability to identify and support promising healthcare ventures.
DNA Capital invests exclusively in the healthcare sector, targeting companies at early, growth, and late stages. The firm emphasizes high-quality investments that align with its ethical standards, operating globally with a particular focus on North and South America. Investment stages include pre-seed, seed, seed-plus, Series A, Series B, Series C, Series D, Series E, and growth equity.
DNA Capital seeks to partner with founders and management teams who are committed to building leading healthcare businesses. The firm looks for innovative solutions in sectors such as healthcare, digital health, health platforms, health insurance technology, medical devices, telemedicine, clinical trials, diagnostics, pharma-tech, and health data. This focused approach allows DNA Capital to leverage its extensive network and operational expertise to enhance the growth and scalability of its portfolio companies.
DNA Capital's portfolio includes a diverse range of healthcare companies, showcasing its commitment to various sectors within the industry. Notable portfolio companies include:
These companies represent a mix of innovative solutions and established players in the healthcare market, reflecting DNA Capital's strategic focus on high-quality investments.
José Eduardo Guinle: Partner with extensive experience in healthcare investments and a background in management consulting.
Mario Sergio Ribeiro: Partner specializing in healthcare technology and innovation, with a history of successful investments in the sector.
Partha Mishra: Partner focused on operational excellence and strategic growth within portfolio companies.
Pedro Bueno: Partner and key figure in the firm, known for his leadership in the Bueno family's healthcare ventures.
Thayan Hartmann: Partner with expertise in healthcare services and market expansion strategies.
Luiz Noronha: Partner with a strong background in finance and investment management.
Lucas Cortez: Vice President, contributing to deal sourcing and portfolio management.
Ricardo Lima: CFO, overseeing financial operations and strategic planning.
Constanza Cortes: Director of Investor Relations & Marketing, responsible for managing relationships with investors and stakeholders.
Julia Prado: Private Equity Associate, focusing on investment analysis and portfolio support.
To pitch DNA Capital, founders should use the contact form available at dnacapital.com/contact or send an email to contact@dnacapital.com. It is important to include a comprehensive pitch deck that outlines the business model, market analysis, and financial projections. DNA Capital appreciates detailed information that demonstrates the startup's potential for growth and alignment with their investment thesis.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In November 2021, DNA Capital led a $20 million funding round into Memed, a healthtech e-prescribing platform, alongside Temasek and Fit Participações. This investment allowed DNA Capital to assume control of Memed, enhancing its portfolio in the digital health space.
In 2023, DNA Capital continued to expand its influence in the healthcare sector by participating in multiple funding rounds for Brazilian healthtech startups, collaborating with notable investors such as Kaszek and SP Ventures.
What are DNA Capital's investment criteria?
DNA Capital invests exclusively in the healthcare sector, focusing on companies at various stages, including pre-seed, seed, Series A, and growth equity. The firm emphasizes ethical and humane products and services, seeking high-quality investments that align with its values.
How can I pitch DNA Capital?
Founders can pitch DNA Capital through their website at dnacapital.com/contact or via email at contact@dnacapital.com. It is advisable to include a detailed business plan and financial projections in the pitch.
What makes DNA Capital different from other investors?
DNA Capital's exclusive focus on healthcare and its deep connections within the industry, particularly through the Bueno family's strategic holdings, provide unique insights and resources that enhance the growth potential of portfolio companies.
What is the geographic scope of DNA Capital's investments?
The firm operates globally, with a particular emphasis on North America and Latin America. This geographic focus allows DNA Capital to tap into diverse healthcare markets and opportunities.
What is the typical check size for investments?
While specific check sizes are not disclosed, DNA Capital invests across multiple stages, indicating a range of investment amounts from early-stage funding to larger growth equity rounds.
What kind of support does DNA Capital provide to its portfolio companies?
DNA Capital adds value through its extensive network and operational expertise, leveraging the Bueno family's strategic holdings in healthcare to provide unique insights and access to resources that enhance growth and scalability.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.